IL-33/ST2 may play an important role in the modulation of antitumor immunity in STS by promoting the recruitment of CD8+ T cells and enhancing IFN-γ production, as well as by antagonizing Tregs, MDSCs, and TGF-β1-mediated immunosuppression (Figure 6). The gene discussed is CD8A; the disease is telomere syndrome.